Physician-Led Health Tech Startup Scales Therapeutic Plasma Exchange (TPE) Nationwide Amid Rise in Diseases Linked to Toxins
CHICAGO (July 12, 2025) — MDLifespan, a physician-led health technology company focused on environmental toxin reduction through Advanced Serial Therapeutic Plasma Exchange (TPE) protocols, today announced a major nationwide expansion of its protocols into eight additional states, with more locations slated to open through Q3 and Q4 2025.
New MDLifespan centers are now operating or in development in Florida, Illinois, Ohio, New Jersey, Arizona, Colorado, Texas, and Michigan, expanding access to physician-led Advanced Therapeutic Plasma Exchange protocols designed to address environmental toxin burden and support long-term health.
“Environmental toxins are THE silent drivers of today’s most devastating diseases — from neurodegeneration to cardiovascular disease, immune dysfunction, cancer, chronic fatigue, and infertility. MDLifespan exists to remove them,” said Paul Savage, MD, founder and CEO of MDLifespan. “We are physician-led for a reason: our protocols are designed to identify and eliminate the toxins that matter most for health outcomes — not just to move blood through a machine.”
Expanding Access to Advanced Therapeutic Plasma Exchange
MDLifespan’s expansion builds on its Advanced Serial Therapeutic Plasma Exchange protocols, which combine Therapeutic Plasma Exchange with proprietary diagnostics and additional supportive protocols.
Therapeutic Plasma Exchange is an established medical procedure that separates and removes plasma before replacement. MDLifespan has developed a structured, multi-session approach that incorporates diagnostic testing, biomarker monitoring, and individualized protocols focused on environmental toxin exposure and inflammatory burden.
The company’s protocols include MDL Brain, MDL Heart, MDL Immunity, MDL Anti-Cancer, MDL Longevity, and MDL Toxin, with each designed around different health priorities and biomarker considerations.
The protocols are intended to address environmental compounds and inflammatory factors that may be relevant to individual patients, including microplastics, pesticides, PFAS, mold toxins, toxic metals, and inflammatory proteins.
Research on Environmental Toxins and Biomarkers
MDLifespan’s approach is informed by emerging research examining environmental exposures, circulating compounds, inflammation, and their potential relationship to long-term health.
A peer-reviewed study published in Medical Hypotheses examined a physician-designed protocol combining serial Therapeutic Plasma Exchange with nutritional supplementation. The study reported reductions in several measured compounds and inflammatory markers in the study population.
The original 2025 release cited reductions including:
- 99% reduction in phthalates
- 85% reduction in lead
- 75% reduction in glyphosate
- 95% reduction in inflammatory markers
These findings represent results reported in the study and should be interpreted within the context of the study population, methodology, and limitations rather than as a guarantee of individual patient outcomes.
MDL Mold Protocol Expands Nationwide
As part of the nationwide expansion, MDLifespan also announced the launch of its MDL Mold Protocol, co-developed with mold illness expert Dr. Jill Carnahan.
The protocol is designed specifically around patients concerned about mold-related environmental exposures and circulating mold toxins. It combines Advanced Therapeutic Plasma Exchange with supporting nutritional and diagnostic strategies.
The original announcement reported up to a 90% reduction in measured circulating mold toxins, compared with approximately 17% with oral binders and approximately 30% with standard TPE protocols. These figures reflect reported protocol results and should not be interpreted as a guarantee of toxin removal for every patient.
“We’re not just scaling access to TPE — we’re scaling measurable outcomes that matter to patients and practitioners,” said Dr. Savage. “This is the future of regenerative medicine.”
A Growing National Network
The expansion extends MDLifespan’s physician-led Advanced TPE model into additional markets across the United States.
New MDLifespan locations were operating or in development in:
- Florida
- Illinois
- Ohio
- New Jersey
- Arizona
- Colorado
- Texas
- Michigan
The expansion reflects the company’s broader strategy of working with physicians and established clinical organizations to make Advanced Serial Therapeutic Plasma Exchange more accessible in physician-led outpatient settings.
As MDLifespan continues to expand, its protocols remain centered on diagnostic evaluation, individualized planning, and monitoring of biomarkers and environmental toxin burden.
Learn More or Find a Location
MDLifespan’s Advanced Therapeutic Plasma Exchange protocols are available through locations across the United States, with additional locations planned as part of the company’s 2025 expansion.
Patients and practitioners can explore MDLifespan’s locations and available protocols through the company’s website.
To learn more about the science and clinical development of Advanced TPE, readers can also explore MDLifespan’s research and educational resources.
Originally published via our press platform and republished in our official newsroom.